News & Media

Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

Featured Article in Global Family Office Journal – A Proud Moment for Swiss Rockets

Rocketvax Achieves Major Breakthrough in Live-Attenuated SARS-CoV-2 Vaccine Development

Swiss Rockets AG Announces Key Appointments to Leadership Team

Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Torqur AG Presents Interim Phase 2 Clinical Trial Results at American Academy of Dermatology

Spotlight on Leadership: Dr. Vladimir Cmiljanovic in The CEO Magazine

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX(TM) Platform and Next-Generation Nasal COVID-19 Vaccine

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

Promising Next-Generation SARS-CoV-2 Live Vaccine Demonstrates Remarkable Safety, Protection, and Immunity Profile in Pre-Clinical Studies

Rocketvax Announces Collaboration with the US National Institutes of Health (NIH) for Clinical Trial of Nasal, Live-Attenuated NextGen SARS-CoV-2 Vaccine

Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis

Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib

New study on the benefits of COVID-19 nasal spray vaccination published in "Nature Communications"